Skip ads and navigation
Advertising
Our network sites seattlepi.comHelp
Print thisE-mail this
Most influential in biotech: Bruce Carter

Second in a series. I asked seven of the top biotech leaders in the city to name three colleagues who they thought were the most influential players in the industry here. This week, I'll showcase the names that came up most often among their responses.

Please e-mail me your own selections at joetartakoff@seattlepi.com. I'll showcase those on Friday.

At ZymoGenetics, CEO Bruce Carter is overseeing the launch of the company's first product, Recothrom, a synthetic protein designed to stop bleeding during surgery. It's too early to tell if the product is gaining much ground (some analysts say the launch is taking longer than expected) but Carter has promised that "We will be finished when we dominate this market."

Picture
Bruce Carter

Carter's accomplishments at ZymoGenetics are many. He led the negotiations that culminated in the spin off of ZymoGenetics from Novo Nordisk in 2000 and then oversaw the company's initial public offering two years later.

He has also negotiated partnerships with Merck Serono (jointly the two companies are developing Atacicept for the treatment of autoimmune, inflammatory diseases and cancer) and Bayer Schering (to commercialize Recothrom overseas and co-promote it in the United States). And despite recent layoffs, Carter still oversees a staff of 535 biotech employees that is second in number only to Amgen in the region.

Last month, Carter was tapped to lead the search for a new president of the Washington Biotechnology and Biomedical Association.

He is revered by his peers.

Says A. Bruce Montgomery, head of respiratory therapeutics at Gilead Sciences:

Influence requires outside the company action, respect, and likely internal success ... That said, I cast my three votes for Bruce Carter. He is in his own class. A former Olympian ... , scientist, business man, community man, and the guy you want to go have a drink with. His Churchill imitation is priceless. I sign my email to him as Bruce II, as I share a name with a giant, but clearly I am the lessor.

Adds Clay Siegall, CEO of Seattle Genetics:

He is the dean of all the corporate executives in town.

About that reference to the Olympics: Carter rowed with Great Britain's 8-man sweep boat in the 1968 Olympics in Mexico City.

Posted by at June 24, 2008 11:00 a.m.
Categories: ,
Comments
There are currently no comments for this blog entry.

! Login below to post a comment.

Registered users, log in here
E-mail 
Password 
Remember me
 HELP! I forget my password

Unregistered users, sign up now

Or post anonymously (About this feature)

Your comment (No HTML allowed, use these special codes instead)
Violating our Terms of Service may result in your post being removed.

Special codes
  • [b]selected text[/b] -- Display the selected text in bold.
  • [i]selected text[/i] -- Display the selected text in italics.
  • [link]www.seattlepi.com[/link] -- Creates a link to the url between the link tags.
  • [link title="Seattle Post-Intelligencer"]www.seattlepi.com[/link] -- Creates a link to the url between the link tags, uses title as link text.
  • [mail]newmedia@seattlepi.com[/mail] -- Creates a link to an email address.
Enter the code shown:
What is this?
SUBSCRIBE

RSS
Headline widget

BLOGGER BIO
photo
Joe Tartakoff: P-I staff reporter
CONTACT INFO

News tips or comments? E-mail me or call directly, 206-448-8293.

TOP OF THE BLOG

Most popular posts in July, by page views
1. Dendreon initiates new Provenge study
2. Allen Institute releases spinal cord map
3. Genentech, Roche – and Seattle Genetics

Q & As

Excerpts from interviews
· Don Foster on Novo Nordisk
· Bruce Carter on ZymoGenetics
· Lee Huntsman on the Life Sciences Discovery Fund
· Clay Siegall on Seattle Genetics
· J. Michael French on MDRNA
· Jack Faris on the WBBA

THE INFLUENTIAL

A series on the blog taking stock of Seattle's biotech leaders
· Who are Seattle's most influential biotech leaders?
· The CEO: Bruce Carter
· The entrepreneur: Bruce Montgomery
· The investor: Alan Frazier
· Your choices

THE STATE OF BIOTECH

A series on the blog
· Seattle's contracting biotech job market
· Venture capital numbers here don't measure up
· A fall in the market value of local firms

ARCHIVES
Search this blog

Recent entries
· Stories to watch: ZGEN and SGEN
· Round-up: Dendreon, SonoSite
· Stories to watch: Provenge
· Stories to watch: Amgen's Elliott Bay plans
· Round-up: Cell Therapeutics, Amgen

Browse by month
Browse by category

RSS/Web feeds (help)
RSS 2.0RSS 1.0Atom
Headlines for your site

LINKS

Blogs
· Pharmalot
· John Cook's Venture Blog
· blog.bioethics.net
· Eye on FDA
· In the Pipeline
· IN VIVO Blog
· The Biotech Weblog
· DrugWonks
· Biotech Blog
· BioHealth Investor
· Xconomy Seattle
· Andy's Take

Groups
· Washington Biotechnology and Biomedical Association
· Northwest Association for Biomedical Research

Rumors
· Biofind

Jobs
· WBBA Careers
· Medzilla
· BioJobBlog

Resources
· Clinicaltrials.gov

Most recent posts
· East-West Blend: Blindness: Stereotype or Metaphorical Genius?
· Seattle Neighborhood Buzz: Update: Council approves cafe proposal
· Seattle 911: Contest: Name that serial bank robber

*Would you like to blog for us?

ADVERTISING
Advertising

Seattle Post-Intelligencer
101 Elliott Ave. W.
Seattle, WA 98119
(206) 448-8000

Home Delivery: (206) 464-2121 or (800) 542-0820
seattlepi.com serves about 1.7 million unique visitors
and 30 million page views each month.

Send comments to newmedia@seattlepi.com
Send investigative tips to iteam@seattlepi.com
©1996-2007 Seattle Post-Intelligencer
Terms of Use/Privacy Policy

Hearst Newspapers